https://lrrk2-receptor.com/ind....ex.php/long-term-res
The Cardiac Review and Evaluation Committee Criteria were used to determine cardiotoxicity. Baseline faculties and outcomes (final kept ventricular ejection fraction, improvement in LVEF, trastuzumab interruption) had been contrasted in clients with and without cardiotoxicity. Cardiac attention and therapy received were taped. Sixty patients (mean age 52 ± 10.4 years) were included. The median trastuzumab exposure was 37 cycles (interquartile range 23 to 56) over 28 months (int
Like
Comment
Share
